Clinical trial
Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome
NCT00272844 · Boston Children's Hospital, Other · Completed
Key facts
| NCT number | NCT00272844 |
|---|---|
| Title | Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome |
| Official title | Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome |
| Lead sponsor | Boston Children's Hospital, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Smith-Lemli-Opitz Syndrome |
| Intervention type | Drug |
| Interventions | crystalline cholesterol oil-based suspension |
| Enrollment | 23 |
| Start date | Jan 1, 1998 |
| Primary completion | Jun 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Jan 9, 2006 |
| Last update posted | Oct 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: